Compare WAFD & HTFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | WAFD | HTFL |
|---|---|---|
| Founded | 1917 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.2B |
| IPO Year | 1996 | 2025 |
| Metric | WAFD | HTFL |
|---|---|---|
| Price | $28.44 | $55.54 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 10 |
| Target Price | $34.50 | ★ $47.22 |
| AVG Volume (30 Days) | 1.1M | ★ 1.2M |
| Earning Date | 10-15-2026 | 11-12-2026 |
| Dividend Yield | ★ 3.80% | N/A |
| EPS Growth | 5.20 | ★ 82.37 |
| EPS | ★ 2.45 | N/A |
| Revenue | $29,650,000.00 | ★ $176,034,000.00 |
| Revenue This Year | $127.22 | $41.33 |
| Revenue Next Year | $21.56 | $24.23 |
| P/E Ratio | $11.62 | ★ N/A |
| Revenue Growth | 7.79 | ★ 39.92 |
| 52 Week Low | $28.43 | $20.13 |
| 52 Week High | $39.49 | $54.32 |
| Indicator | WAFD | HTFL |
|---|---|---|
| Relative Strength Index (RSI) | 26.93 | 56.88 |
| Support Level | N/A | $46.46 |
| Resistance Level | $33.59 | $52.38 |
| Average True Range (ATR) | 0.61 | 2.75 |
| MACD | 0.07 | -0.24 |
| Stochastic Oscillator | 1.61 | 62.86 |
WaFd Inc is engaged in providing lending, depository, insurance, and other banking services to consumers, mid-sized to large businesses, and owners and developers of commercial real estate. Through the WaFd Bank, it is involved in accepting deposits from the general public and investing these funds in loans of various types, including first-lien mortgages on single-family dwellings, construction loans, land acquisition and development loans among others. The Bank also invests in certain United States government and agency obligations along with other investments and also performs insurance brokerage activities. Geographically, it operates in Washington, Oregon, Idaho, Arizona, Utah, Nevada, New Mexico, California and Texas.
HeartFlow Inc is a commercial-stage medical technology company that provides software and artificial intelligence (AI) designed to deliver a non-invasive solution for diagnosing and managing coronary artery disease. The company operates and manages its business as a single reportable operating segment: non-invasive coronary artery disease detection solutions. Geographically, it operates in the United States and the rest of Europe, deriving the majority of its revenue from the United States. The company has developed three software products: Heartflow Roadmap Analysis, Heartflow FFRCT Analysis, and Heartflow Plaque Analysis.